Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 1 client • 7 examiners • 6 art units • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
This profile records 6 pending office actions in Biotechnology & Pharmaceuticals. The career record includes 12721 applications, so the current activity is presented against a large overall prosecution portfolio. The technology area calls for attention to scientific disclosure and the boundaries of biologically based claims.
The resolved allowance rate is 73.14%, and the average is 3.51 office actions per allowance. These figures provide context for resolved results and examination activity, but they do not change the separate significance of the pending docket for current workload planning.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §112 only | 2 (29%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
| STEPHENS, AMELIA CAROLE | 1 | 75.0% | +50.0% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
| WHALEY, PABLO S | 1 | 25.0% | +21.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17334109 | METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | WHALEY, PABLO S | 20d |
| 18645261 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | BUNNER, BRIDGET E | — |
| 18008146 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | GOLDBERG, JEANINE ANNE | — |
| 18008150 | METHODS AND SYSTEMS FOR MEASURING POST-OPERATIVE DISEASE RECURRENCE | VANN-OJUEKAIYE, KENDRA RAYCHELL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17334109 | METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | WHALEY, PABLO S | 20d |
| 18326912 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | HUDSON, AMY ROSE | 46d |
| 18546947 | ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG | STEPHENS, AMELIA CAROLE | 50d |
| 18645261 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | BUNNER, BRIDGET E | — |
| 18546938 | COMPOSITIONS COMPRISING HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | SHUPE, ELIZABETH A | — |
| 18008146 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | GOLDBERG, JEANINE ANNE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Cedars-Sinai | 7 |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1647 | 1 |
| 1643 | 1 |
| 1645 | 1 |
| 1636 | 1 |
| 3619 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18645261 | HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | Cedars-Sinai Medical Center | BUNNER, BRIDGET E | 1647 | §102§112Other | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18546938 | COMPOSITIONS COMPRISING HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF | Cedars-Sinai Medical Center | SHUPE, ELIZABETH A | 1643 | §103DP | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18546947 | ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG | Cedars-Sinai Medical Center | STEPHENS, AMELIA CAROLE | 1645 | §103DP | Final Rejection | 50d | Pending | Aug 17, 2023 |
| 18326912 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center | HUDSON, AMY ROSE | 1636 | §112 | Final Rejection | 46d | Pending | May 31, 2023 |
| 18008146 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | Cedars-Sinai Medical Center | GOLDBERG, JEANINE ANNE | 1682 | §101§112DP | Non-Final OA | — | Pending | Dec 02, 2022 |
| 18008150 | METHODS AND SYSTEMS FOR MEASURING POST-OPERATIVE DISEASE RECURRENCE | Cedars-Sinai Medical Center | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112Other | Final Rejection | — | Pending | Dec 02, 2022 |
| 17334109 | METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | Cedars-Sinai Medical Center | WHALEY, PABLO S | 3619 | §112 | Final Rejection | 20d | Pending | May 28, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial73.1% of resolved applications prosecuted by Jones Day For Merck-Pbi-Csmc were allowed, across 12,721 applications in USPTO records.
3.51 office actions per allowed application on average.
7 pending office actions as of October 2026, for 1 client, before 7 examiners in 6 art units.
